Biocon Biologics will expand its biosimilar oncology portfolio, including biosimilars for Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The company will outline its integration as a wholly-owned subsidiary into Biocon Ltd., strengthening its leadership in biosimilar insulins and GLP-1 peptide generics. These plans will be discussed at the 2026 J.P. Morgan Healthcare Conference. The integration will better position the company in diabetes, oncology, and immunology.
Oncology Portfolio Expansion
Biocon Biologics is set to introduce three new biosimilar oncology assets: biosimilars for Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®). This addition, which includes two PD-1 inhibitors, will create one of the most comprehensive oncology portfolios in the industry.
Global sales of Keytruda were $29.5 billion in 2024, Opdivo sales were $9.3 billion, and Herceptin SC and Herceptin HYLECTA combined sales were $1.72 billion. This expansion represents a significant opportunity in the oncology pharmaceutical market, estimated at over $75 billion.
Corporate Integration Plans
Biocon Limited plans to integrate Biocon Biologics as a wholly-owned subsidiary. This integration is intended to leverage the global commercial infrastructure, simplify the corporate structure, and strengthen Biocon’s position in diabetes, oncology, and immunology.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, stated that this integration will strengthen the company’s ability to deliver biosimilars and generics at a global scale and enhance access to affordable, high-quality medicines. The integration is expected to be completed no later than March 31, 2026.
Source: BSE
